Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Long-Term Deferred Tax (2016 - 2025)

Haemonetics has reported Long-Term Deferred Tax over the past 16 years, most recently at $7.3 million for Q4 2025.

  • Quarterly results put Long-Term Deferred Tax at $7.3 million for Q4 2025, down 8.39% from a year ago — trailing twelve months through Dec 2025 was $7.3 million (down 8.39% YoY), and the annual figure for FY2025 was $7.8 million, up 0.83%.
  • Long-Term Deferred Tax for Q4 2025 was $7.3 million at Haemonetics, down from $7.6 million in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for HAE hit a ceiling of $9.4 million in Q2 2024 and a floor of $4.3 million in Q4 2022.
  • Median Long-Term Deferred Tax over the past 5 years was $6.1 million (2021), compared with a mean of $6.4 million.
  • Biggest five-year swings in Long-Term Deferred Tax: dropped 29.39% in 2022 and later skyrocketed 92.18% in 2024.
  • Haemonetics' Long-Term Deferred Tax stood at $6.1 million in 2021, then fell by 20.15% to $4.8 million in 2022, then rose by 4.71% to $5.1 million in 2023, then surged by 57.79% to $8.0 million in 2024, then fell by 8.39% to $7.3 million in 2025.
  • The last three reported values for Long-Term Deferred Tax were $7.3 million (Q4 2025), $7.6 million (Q3 2025), and $7.8 million (Q2 2025) per Business Quant data.